Join
Live feed
·
PRReleasevia Quantisnow
Cognition Therapeutics Inc. logo

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

ByQuantisnow·Wall Street's wire, on your screen.
CGTX· Cognition Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CGTX (Cognition Therapeutics Inc.) and more on Quantisnow.